Therefore, a therapeutic intervention to inhibit the transition to heart failure through HDAC inhibition and HDAC2 modulation, such as CK2 inhibition16 or activation of PPP2CA, may be a promising strategy for pathological cardiac hypertrophy. This evidence concerns the gene HDAC2 and heart failure.